In this context, our results propose a novel antiangiogenic approach using an inhibitor of EMMPRIN-VEGFR-2 interaction, which would be expected to be specific for tumor angiogenesis, as EMMPRIN is known to be highly expressed in cancer tissues. Here, BSG is linked to cancer.